Tenaya Therapeutics (TNYA -2.99%), a clinical-stage biotechnology company focused on genetic therapies for heart disease, released second-quarter results on August 6, 2025. Tenaya posted a net loss per share of $(0.14) (GAAP) for Q2 2025, narrower than the $(0.19) loss analysts had predicted. This represented a significant year-over-year improvement from a GAAP loss of $(0.34) per share in Q2 2024. The period showed meaningful drops in both research and administrative spending, a reduced net loss (GAAP), an ...